Physician profile
Robert T Galey
NPI 1093259640
$2,492.30
in general payments reported to CMS, 2019-2025
25 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $582 · 2022: $599 · 2023: $582 · 2024: $614 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,290 · Entertainment: $20.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,290.22 |
| Entertainment | $20.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $719.07 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $599.74 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $219.83 | 2021-2023 | Xifaxan |
| Novo Nordisk INC | $135.14 | 2022-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.23 | 2021-2022 | |
| Boston Scientific Corporation | $90.83 | 2022-2024 | |
| Glaxosmithkline, LLC. | $79.06 | 2021-2023 | Trelegy Ellipta |
| Amgen INC. | $78.69 | 2021-2025 | Krystexxa |
| Lilly USA, LLC | $59.98 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Organon LLC | $56.38 | 2022-2023 | Nexplanon |
| Pfizer INC. | $43.30 | 2021 | |
| Saluda Medical Americas, INC. | $41.06 | 2024 | Evoke |
| Otsuka America Pharmaceutical, INC. | $31.50 | 2024 | Rexulti |
| Abbott Laboratories | $24.86 | 2022 | |
| Phadia US INC. | $23.43 | 2024 | Immunocap |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $22.97 | 2024 | Loreev Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $21.04 | 2021 | |
| Optos, INC. | $20.65 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Merck Sharp & Dohme LLC | $19.87 | 2021 | |
| Intra-Sana Laboratories | $19.29 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Exact Sciences Corporation | $18.57 | 2025 | Cologuard Collection Kit |
| Axonics, INC. | $17.75 | 2024 | Axonics |
| Bayer Healthcare Pharmaceuticals INC. | $17.55 | 2023 | |
| Eisai INC. | $15.49 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Galey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.